Drug intelligence / Profile preview

SBD121

Development stage: Preclinical
Lead developer: Sōlaria Biō
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

SBD121 is a synbiotic medical food being developed by Solarea Bio for the dietary management of rheumatoid arthritis. [1, 5] It is a combination of prebiotic fibers and four food-derived microbial strains that are designed to modulate the gut microbiome. [7] Clinical studies are underway to evaluate its ability to aid in the management of symptoms in patients with early rheumatoid arthritis. [1, 3] The product has been shown to be well-tolerated and the microbial strains have been confirmed to be delivered viably to the gut where they transiently persist. [8, 4]

Beyond the preview

Go deeper on SBD121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBD121.

Explore the full profile